Global Medical Exoskeleton Market, By Type (Lower Body Exoskeletons, Upper Body Exoskeletons, Full Body Exoskeletons, Others (Soft Exoskeletons, Active Exoskeletons, Passive Exoskeletons)), By Mobility(Mobile Exoskeletons, Stationary Exoskeletons, Fixed Exoskeletons), By End User (Rehabilitation Centers, Hospitals, Long Term Care Centers, Homecare Settings, Others (Industrial Sites, Military)), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : Nov 2023

Code : CMI6489

Pages :156

Formats :

Excel and PDF

Industry : Healthcare IT

Market News

Recent Developments:

New product launches:

In June 2022, Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial uses, announced that it had received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its robotic exoskeleton EksoNR for use in multiple sclerosis (MS) patients. EksoNR is the first exoskeleton device to receive FDA clearance for rehabilitation use in patients with MS, an indication that significantly expands the use of the device to a broader patient population.
In November 2021, Ottobock, a leading global innovator in prosthetics, orthotics, and exoskeletons, announced the acquisition of 100 percent of suiteX, a U.S.-based company that emerged from the Robotics and Human Engineering Lab at the University of California at Berkeley and specializes in the research and development of professional and medical exoskeletons.
In January 2021, suiteX announced the launch of a novel wearable exoskeleton: ShieldX. For use by medical personnel who must wear heavy radiation protection aprons, ShieldX relieves the user's shoulders and spine by 100% of the weight of a heavy radiation protection apron. ShieldX aims to reduce neck and back injuries associated with these heavy aprons that shorten careers and limit activities outside of work.

Acquisition and partnerships:

In December 2022, Ekso Bionics, developer and manufacturer powered exoskeleton bionic devices announced the acquisition of the Human Motion and Control ("HMC") business of Parker Hannifin Corporation, a global leader in motion and control technologies. The acquisition includes the Indego exoskeleton product line for the lower extremities as well as the planned development of robot-assisted orthoses and prostheses.
In May 2021, Ekso Bionics Holdings, Inc. announced an expanded partnership with Kindred Healthcare, LLC ("Kindred"), EksoNR, which incorporates a clinically deployed robotic exoskeleton at four of Kindred's Long-Term Acute Care ("LTAC") hospitals in the U.S. The multi-unit contract follows a successful EksoNR pilot program last year.
In March 2021, Ekso Bionics Holdings, Inc. announced a partnership with U.S. Physiatry (USP), a nonprofit organization to educate physicians about the clinical benefits of an EksoNR exoskeleton. USP is the largest inpatient medical practice in the U.S. focused exclusively on physical medicine and rehabilitation. The partnership will help make physicians and other rehabilitation clinicians aware of Ekso Bionics' technology and demonstrate how robotics can be successfully implemented into a rehabilitation program.